Frédéric Duchesne

About Frédéric Duchesne

Frédéric Duchesne is a French executive with deep experience in pharmaceuticals and life sciences, currently associated with Cegedim as a censor. His career has been built across commercial leadership, operational management, and executive roles at major healthcare and pharmaceutical groups. According to the CV published by Cegedim, he has held director and advisory roles since May 2019 and joined Cegedim as a censor in 2019. Before becoming involved with Cegedim, Duchesne spent nearly nine years at Laboratoires Pierre Fabre, where he served until May 2019 as President & CEO of the Pharmaceutical Division. This was a defining leadership role, placing him in charge of a major pharmaceutical business operating in a demanding, regulated, and highly competitive environment. Earlier in his career, he held senior positions at Bristol-Myers Squibb in London and Paris, including Vice President Europe and Managing Director UK, as well as Vice President and Head of Sales Operations for France. He also held leadership responsibilities at GlaxoSmithKline, where he oversaw French sales operations and led a respiratory business unit. His background also includes roles at SmithKline Beecham in both commercial management and supply chain leadership, giving him broad exposure to the pharmaceutical value chain, from logistics and supply management to market execution and growth. This combination of experiences gives Duchesne strong expertise in commercial strategy, business unit leadership, supply chain management, international operations, and pharmaceutical governance. That profile is particularly relevant to Cegedim, a technology and services company serving healthcare professionals, insurers, and related industries, where understanding the operational and regulatory realities of the sector is essential. As censor, he contributes to oversight and governance support within the company’s board framework, a role Cegedim continues to recognize in its governance and remuneration disclosures. Duchesne has also broadened his activity through mandates in healthcare innovation, including roles with Sophia Genetics, Midatech Pharma, Charles, and Angels Santé. These appointments suggest a sustained focus on life sciences innovation, scientific advisory work, and support for entrepreneurial healthcare ventures. Overall, his career reflects a blend of executive discipline, sector specialization, and international leadership experience that is well aligned with the strategic needs of a listed healthcare technology group such as Cegedim.